AbbVie Inc. /
Landos Biopharma, Inc.
AbbVie completes acquisition of Landos Biopharma, Inc.
What happened
AbbVie completed its acquisition of Landos Biopharma, Inc. on May 23, 2024. Landos’ lead investigational asset, NX-13, is in Phase 2 for moderate to severe ulcerative colitis.
The aggregate closing amount was approximately $137.5 million.
The source
Everything on this page comes from the source below.
AbbVie completes acquisition of Landos Biopharma, Inc.
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly